BCRX

BIOCRYST PHARMACEUTICALS, INC.

BCRX · CIK 882796 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20182025
Net Income$264M
20182025
Operating CF$347M
20182025
Free Cash Flow
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue————————
Cost of Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Gross Profit————————
R&D Expense$0.2B$0.2B$0.2B$0.3B$0.2B$0.1B$0.1B$0.1B
SG&A Expense$0.3B$0.3B$0.2B$0.2B$0.1B$0.1B$0.0B$0.0B
Operating Income$0.3B$-0.0B$-0.1B$-0.1B$-0.2B$-0.2B$-0.1B$-0.1B
Net Income$0.3B$-0.1B$-0.2B$-0.2B$-0.2B$-0.1B$-0.0B$-0.0B
EPS (Basic)$1.26$-0.43$-1.18$-1.33————
EPS (Diluted)$1.21$-0.43$-1.18$-1.33————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.5B$0.5B$0.5B$0.6B$0.6B$0.3B$0.2B$0.1B
Current Assets$0.4B$0.4B$0.5B$0.5B$0.6B$0.3B$0.2B$0.1B
Cash & Equivalents$0.1B$0.1B$0.1B$0.3B$0.5B$0.3B$0.1B$0.0B
Total Liabilities$0.6B$1.0B——————
Current Liabilities$0.2B$0.2B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Stockholders' Equity$-0.1B$-0.5B$-0.5B$-0.3B$-0.1B$-0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$0.3B$-0.1B$-0.1B$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B
Investing Cash Flow$-0.0B$0.1B$-0.1B$-0.1B$0.0B$-0.0B$0.1B$0.0B
Capital Expenditures——————$0.0B—
Financing Cash Flow$-0.3B$-0.0B$0.0B$0.1B$0.4B$0.3B$0.1B$0.1B
← Companies